A recent paper published in the New England Journal of Medicine calls for regulations to protect customers’ personal and genetic data in light of biotech company 23andMe’s uncertain future.
The genetic testing firm became wildly popular after launching in 2007, with millions of customers sending in saliva samples for analysis to learn about their ancestry and genetic makeup.
The company was valued at $6 billion, or $17.65 a share, shortly after going public in 2021. It has since fallen to about $48 million, or $1.78 per share, after a 2023 data breach and resignation of some board members. The firm said in January that it’s exploring “strategic alternatives,” including a sale of the company or assets, restructuring, or…
